Novel technologies for diagnosing and monitoring pulmonary diseases

IRAS ID 187325

This is a collaborative study between academia and the NHS which seeks to harness the latest scientific advances to improve the care of patients with different respiratory diseases.

We are indebted to the many patients who have contributed to, and continue to contribute to this study.

Thank you.

This website is for you to see how you are aiding important clinical advances and allows you to contact us should you wish.

'Novel Technologies' launch meeting, April 2016

From left to right:

Top row: Dr. Subhamay Ghosh, Prof. Luis Mur - Scientific Lead, Prof. Keir Lewis - Clinical Lead, Denisa Asandei, Adrian Mironas, Dr. Priya Sai-Giridhar

Bottom row: Dr. Tim Tasibey, Dr. Kirsty Hett, Rachel Paes De Araujo

Research

The 'Novel Technologies' study was launched in April of 2016 and it focuses on identifying important chantges in saliva, sputum, serum and pleural fluids which are linked to:

The presence of lung cancer
A particular stage of lung cancer
A particular type of lung cancer; (e.g. Non-small cell lung cancer [NSCLC]; small cell lung cancer [SCLC])
COPD disease status and the triggering of exacerbation (a flare-up or episode when your breathing gets markedly worse)
informing the treatment of sleep apnoea

Lung Cancer

COPD

Sleep Apnoea

Chief Investigator

Prof. Keir Lewis

Keir Lewis is Professor at Swansea University, Medical Director of Respiratory Innovation Wales and Consultant in Respiratory Medicine at Hywel Dda University Health Board. He is the Clinical Lead for the Novel Technologies Project and helps to frame new questions on biomarkers and helps identify and recruit patients with various lung conditions into the various studies.

Respiratory Research Assistant

Sarah Bowen

Sarah Bowen Respiratory Research Assistant at Prince Philip Hospital Hywel Dda University Health Board. She provides day to day admin support for the Novel Technologies project, site file maintenance and co-ordinating sample transfers.

Prinicpal Investigator

Prof. Luis Mur

Prof. Mur is based at Aberystwyth University. He uses the latest 'omic approaches to develop our knowledge of a range of pathologies. He is visiting Professor of UNESP (Sao Paulo) in Brazil, the University of Silesia in Poland and Northwest University in China. He has "recognised foreign expert" status at Shandong University, China.

MD researcher

Dr. Scott O'Rourke

Scott is research for his MD and focusing on biochemical changes in blood that occurs with sleep apnoea and its treatment

PhD Researcher

Tina Kramaric

Tina is working to apply metabolomics (wide-ranging biochemical anlayses) to aim in the diagnosis of a range of respiratory diseases, including lung cancer and COPD

MPhil Researcher

Andrine Vangberg

Andrine is working to establish biochemical changes in urine that are linked to the lung cancer; its stage and type.

"Novel Tech" publications

T Kramarić, RP de Araujo, K Love, T Asibey-Berko, S Ghosh, KE Lewis, LAJ Mur. (2022) Systemic changes in monoacylglycerols could be an indicator of inflammation in chronic obstructive pulmonary disease (COPD) patients Thorax 77 (Suppl 1), A90-A91

O’Rourke, S.; Thomas, S.; Lewis, C.; Bowen, S.; Mur, L.; Lewis, K. 13 (2021) The effect of continuous positive airway pressure (CPAP) on key plasma metabolites identifying obstructive sleep apnoea hypopnoea syndrome (OSAHS). BMJ Open Respiratory Research 2021, 8, A6-A7, doi:10.1136/bmjresp-2021-bssconf.11.

Wolffs, K.L.; Mansfield, B.; Bruce, R.T.; Huang, P.; Schepelmann, M.; Brennan, S.C.; Verckist, L.; Adriaensen, D.; De Araújo, R.P.; Mur, L.A.J., et al. Calcium-sensing receptor antagonism as a novel therapeutic for pulmonary fibrosis. medRxiv 2020, 10.1101/2020.03.12.20034751, 2020.2003.2012.20034751, doi:10.1101/2020.03.12.20034751.

Mansfield, B.; Ho, T.-R.; Mudway, I.; Lugg, S.T.; Corrigan, C.J.; Ward, J.P.T.; Thickett, D.; Prytherch, Z.; Scofield, S.; Kemp, P.J., et al. Calcium-sensing receptor antagonists, calcilytics, prevent activation of human dendritic and epithelial cells by urban particulate matter. European Respiratory Journal 2020, 56, 1970, doi:10.1183/13993003.congress-2020.1970.

Kramarić, T.; Thomas, S.; Love, K.; Bond, I.; Rooke, D.; Mur, L.; Lewis, K. Late Breaking Abstract - Early exploratory use of omic approaches to assess metabolite changes in COPD. European Respiratory Journal 2020, 56, 322, doi:10.1183/13993003.congress-2020.322.

Paes de Araujo, R.; Bertoni, N.; Seneda, A.L.; Felix, T.F.; Carvalho, M.; Lewis, K.E.; Hasimoto, E.N.; Beckmann, M.; Drigo, S.A.; Reis, P.P., et al. Defining Metabolic Rewiring in Lung Squamous Cell Carcinoma. Metabolites 2019, 9, doi:10.3390/metabo9030047.

Mansfield, B.; Huang, P.; Bruce, R.; Ho, T.-R.; Du, X.; Huang, Q.; Wang, W.; Lugg, S.; Ford, W.; Kidd, E., et al. T4 Calcium-sensing receptor antagonists (calcilytics) as a novel therapeutic for alarmin-driven inflammatory lung disease. Thorax 2019, 74, A2-A3, doi:10.1136/thorax-2019-BTSabstracts2019.4.

Mur, L.; Mironas, A.; Paes, R.; O'Shea, K.; Lewis, K. Non-targeted integrative multi-omics approaches on sputum reveal potential diagnostic and monitoring biomarkers for respiratory diseases. European Respiratory Journal 2017, 50, PA375, doi:10.1183/1393003.congress-2017.PA375.

Funding Bodies

KESS2

Respiratory Innovation Wales